| __timestamp | Celldex Therapeutics, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20622000 | 17986000 |
| Thursday, January 1, 2015 | 33837000 | 32480000 |
| Friday, January 1, 2016 | 35979000 | 68081000 |
| Sunday, January 1, 2017 | 25003000 | 169906000 |
| Monday, January 1, 2018 | 19269000 | 248932000 |
| Tuesday, January 1, 2019 | 15426000 | 354100000 |
| Wednesday, January 1, 2020 | 14456000 | 433300000 |
| Friday, January 1, 2021 | 20488000 | 583300000 |
| Saturday, January 1, 2022 | 27195000 | 752700000 |
| Sunday, January 1, 2023 | 30914000 | 887600000 |
| Monday, January 1, 2024 | 1007200000 |
Unlocking the unknown
In the competitive world of biotechnology, managing costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Neurocrine Biosciences, Inc. and Celldex Therapeutics, Inc. from 2014 to 2023. Over this period, Neurocrine Biosciences has seen a staggering increase in SG&A expenses, growing nearly 50 times from 2014 to 2023. In contrast, Celldex Therapeutics has maintained a more stable expense trajectory, with a modest increase of about 50% over the same period.
The data reveals a strategic divergence: while Neurocrine Biosciences has aggressively expanded its operational spending, possibly to fuel growth and innovation, Celldex Therapeutics has opted for a more conservative approach. This contrast highlights the varied strategies within the biotech sector, where companies balance between cost management and investment in future growth.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Ultragenyx Pharmaceutical Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Neurocrine Biosciences, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Celldex Therapeutics, Inc.
Comparing SG&A Expenses: Lantheus Holdings, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
Cytokinetics, Incorporated or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: TG Therapeutics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights